|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF692 |
Gene summary for ZNF692 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF692 | Gene ID | 55657 |
| Gene name | zinc finger protein 692 | |
| Gene Alias | AREBP | |
| Cytomap | 1q44 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q9BU19 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55657 | ZNF692 | LZE7T | Human | Esophagus | ESCC | 2.96e-11 | 4.52e-01 | 0.0667 |
| 55657 | ZNF692 | LZE8T | Human | Esophagus | ESCC | 2.65e-02 | 1.83e-01 | 0.067 |
| 55657 | ZNF692 | LZE24T | Human | Esophagus | ESCC | 5.69e-12 | 2.85e-01 | 0.0596 |
| 55657 | ZNF692 | P1T-E | Human | Esophagus | ESCC | 9.27e-11 | 4.56e-01 | 0.0875 |
| 55657 | ZNF692 | P2T-E | Human | Esophagus | ESCC | 1.53e-19 | 3.25e-01 | 0.1177 |
| 55657 | ZNF692 | P4T-E | Human | Esophagus | ESCC | 4.00e-07 | 1.64e-01 | 0.1323 |
| 55657 | ZNF692 | P5T-E | Human | Esophagus | ESCC | 1.28e-19 | 2.92e-01 | 0.1327 |
| 55657 | ZNF692 | P8T-E | Human | Esophagus | ESCC | 1.31e-11 | 2.04e-01 | 0.0889 |
| 55657 | ZNF692 | P9T-E | Human | Esophagus | ESCC | 1.75e-09 | 2.20e-01 | 0.1131 |
| 55657 | ZNF692 | P10T-E | Human | Esophagus | ESCC | 2.37e-16 | 2.65e-01 | 0.116 |
| 55657 | ZNF692 | P11T-E | Human | Esophagus | ESCC | 1.38e-06 | 2.55e-01 | 0.1426 |
| 55657 | ZNF692 | P12T-E | Human | Esophagus | ESCC | 5.77e-22 | 3.76e-01 | 0.1122 |
| 55657 | ZNF692 | P15T-E | Human | Esophagus | ESCC | 2.77e-10 | 2.56e-01 | 0.1149 |
| 55657 | ZNF692 | P16T-E | Human | Esophagus | ESCC | 6.68e-22 | 3.45e-01 | 0.1153 |
| 55657 | ZNF692 | P20T-E | Human | Esophagus | ESCC | 1.14e-08 | 2.29e-01 | 0.1124 |
| 55657 | ZNF692 | P21T-E | Human | Esophagus | ESCC | 3.34e-13 | 2.40e-01 | 0.1617 |
| 55657 | ZNF692 | P22T-E | Human | Esophagus | ESCC | 1.53e-12 | 2.26e-01 | 0.1236 |
| 55657 | ZNF692 | P23T-E | Human | Esophagus | ESCC | 1.44e-12 | 2.91e-01 | 0.108 |
| 55657 | ZNF692 | P24T-E | Human | Esophagus | ESCC | 8.05e-04 | 1.14e-01 | 0.1287 |
| 55657 | ZNF692 | P26T-E | Human | Esophagus | ESCC | 7.44e-17 | 2.70e-01 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00059969 | Esophagus | ESCC | monosaccharide metabolic process | 159/8552 | 257/18723 | 1.11e-07 | 1.81e-06 | 159 |
| GO:00193189 | Esophagus | ESCC | hexose metabolic process | 147/8552 | 237/18723 | 2.63e-07 | 3.94e-06 | 147 |
| GO:00060069 | Esophagus | ESCC | glucose metabolic process | 119/8552 | 196/18723 | 1.51e-05 | 1.36e-04 | 119 |
| GO:00442626 | Esophagus | ESCC | cellular carbohydrate metabolic process | 160/8552 | 283/18723 | 1.43e-04 | 9.66e-04 | 160 |
| GO:00160514 | Esophagus | ESCC | carbohydrate biosynthetic process | 117/8552 | 202/18723 | 2.96e-04 | 1.79e-03 | 117 |
| GO:00620129 | Esophagus | ESCC | regulation of small molecule metabolic process | 184/8552 | 334/18723 | 3.11e-04 | 1.85e-03 | 184 |
| GO:00463643 | Esophagus | ESCC | monosaccharide biosynthetic process | 52/8552 | 82/18723 | 9.03e-04 | 4.61e-03 | 52 |
| GO:00109065 | Esophagus | ESCC | regulation of glucose metabolic process | 71/8552 | 119/18723 | 1.46e-03 | 6.92e-03 | 71 |
| GO:00193193 | Esophagus | ESCC | hexose biosynthetic process | 49/8552 | 78/18723 | 1.69e-03 | 7.81e-03 | 49 |
| GO:00061096 | Esophagus | ESCC | regulation of carbohydrate metabolic process | 101/8552 | 178/18723 | 1.89e-03 | 8.52e-03 | 101 |
| GO:00106755 | Esophagus | ESCC | regulation of cellular carbohydrate metabolic process | 83/8552 | 146/18723 | 4.24e-03 | 1.69e-02 | 83 |
| GO:00060943 | Esophagus | ESCC | gluconeogenesis | 46/8552 | 75/18723 | 4.54e-03 | 1.78e-02 | 46 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF692 | PERI | Breast | DCIS | RPUSD1,PTGER3,CCBE1, etc. | 5.57e-02 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF692 | SNV | Missense_Mutation | c.553N>A | p.Pro185Thr | p.P185T | Q9BU19 | protein_coding | tolerated(0.4) | benign(0.04) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ZNF692 | SNV | Missense_Mutation | novel | c.1535N>G | p.Ser512Cys | p.S512C | Q9BU19 | protein_coding | deleterious(0.04) | benign(0.219) | TCGA-AC-A3BB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
| ZNF692 | SNV | Missense_Mutation | c.277N>T | p.His93Tyr | p.H93Y | Q9BU19 | protein_coding | deleterious(0) | possibly_damaging(0.865) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| ZNF692 | SNV | Missense_Mutation | c.258N>T | p.Gln86His | p.Q86H | Q9BU19 | protein_coding | tolerated(0.06) | possibly_damaging(0.867) | TCGA-D8-A1XK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicine+cyclophosphamide | SD | |
| ZNF692 | SNV | Missense_Mutation | c.619N>A | p.Glu207Lys | p.E207K | Q9BU19 | protein_coding | tolerated(0.14) | probably_damaging(0.968) | TCGA-EW-A1J2-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD | |
| ZNF692 | SNV | Missense_Mutation | novel | c.1015N>A | p.Gly339Ser | p.G339S | Q9BU19 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
| ZNF692 | insertion | In_Frame_Ins | novel | c.133_134insATATCTCTGGAA | p.Leu45delinsHisIleSerGlyIle | p.L45delinsHISGI | Q9BU19 | protein_coding | TCGA-A2-A0EX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ZNF692 | insertion | In_Frame_Ins | novel | c.296_297insTCCCAC | p.Cys99_Ser100insProThr | p.C99_S100insPT | Q9BU19 | protein_coding | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| ZNF692 | insertion | Nonsense_Mutation | novel | c.295_296insTCCTTCTCTTTTGACTTTGCCT | p.Cys99PhefsTer5 | p.C99Ffs*5 | Q9BU19 | protein_coding | TCGA-B6-A0IE-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| ZNF692 | SNV | Missense_Mutation | rs758599570 | c.446G>A | p.Arg149Gln | p.R149Q | Q9BU19 | protein_coding | tolerated(0.47) | benign(0) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD |
| Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |